Congressman Tim Moore's Investment Highlights Genprex's Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Jan 26
Source: Businesswire
Genprex Inc. shares rose by 9.76% and reached a 20-day high amid positive market conditions.
Congressman Tim Moore's investment in Genprex, totaling between $31,000 and $115,000, reflects confidence in the company's future, especially following its lead drug candidate REQORSA's recent updates. The company is also preparing to meet with the FDA to request Investigational New Drug studies, which could lead to human clinical trials, attracting further investor interest amid the stock's volatility.
This investment activity and the upcoming FDA meeting could enhance Genprex's visibility in the market, potentially leading to increased trading volume and interest from other investors.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
